# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 44847 Powder in Healthy Male Subjects

> **NCT02209844** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 72 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 44847
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02209844
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2007-01
- **Final completion:** —
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2014-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02209844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02209844, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 44847 Powder in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02209844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*